Larimar Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Larimar Therapeutics (LRMR).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

1S.Buy

10Buy

Consensus RatingBuy# Analysts11Avg. Consensus PT$15Upside to Avg. PT+432.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 14, 2026	Leerink Partners	Joseph Schwartz	Assumes	Outperform	$13
Aug 5, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$12→$11
Jul 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Assumes	Buy	$10
Jun 30, 2026	Baird	Joel Beatty	PT Cut	Outperform	$7→$5
May 27, 2026	JP Morgan	Tessa Romero	Initiate	Overweight	$9
May 18, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$13→$12
Mar 20, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$12→$13
Mar 3, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$11→$12
Feb 25, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$12→$14
Feb 25, 2026	Wedbush	Laura Chico	Maintained	Outperform	$11
Oct 2, 2025	Oppenheimer	Andreas Argyrides	PT Cut	Outperform	$26→$21
Sep 30, 2025	Wedbush	Laura Chico	PT Cut	Outperform	$15→$11
Sep 30, 2025	Baird	Joel Beatty	PT Cut	Outperform	$10→$7
Aug 19, 2025	JMP Securities	Jonathan Wolleben	Maintained	Market Outperform	$18
Aug 15, 2025	JMP Securities	Jonathan Wolleben	PT Cut	Market Outperform	$22→$18
Jun 25, 2025	Guggenheim	Yatin Suneja	Maintained	Buy	$26
Jun 24, 2025	Wedbush	Laura Chico	PT Cut	Outperform	$17→$15
Jun 24, 2025	Guggenheim	Yatin Suneja	Maintained	Buy	$26
Mar 25, 2025	Guggenheim	Yatin Suneja	Maintained	Buy	$26
Mar 25, 2025	Baird	Joel Beatty	PT Cut	Outperform	$13→$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $7 to $5.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.

Benzinga Newsdesk

Nvidia To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper Sandler, Morgan Stanley, Evercore raised price targets.

Avi Kapoor

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $12.

Benzinga Newsdesk

Larimar Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Larimar Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

PRO
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

PRO
Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

PRO
JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

Nvidia To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Monday

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12

People Also Watch

People Also Watch

Larimar Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Larimar Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

PROHC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

PROBaird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

PROJP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

Nvidia To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Monday

PROWedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12

People Also Watch

People Also Watch

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

PRO
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

PRO
Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

PRO
JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12